If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
104
results.
Updated on
21/02/2026 [07:16:00]
Results 25 to 50 of 104
Absstract of: US20260021146A1
The present disclosure relates to a recombinant expression vector for secretion of a VC1 protein and an attenuated Salmonella strain transformed therewith, and provides: a recombinant expression vector comprising an flgM gene, a VC1 gene, and an flhDC gene; an attenuated Salmonella strain transformed therewith; and a pharmaceutical composition for cancer treatment, comprising the attenuated Salmonella strain.
Absstract of: CN120826235A
Techniques for providing immunogenic compositions (e.g., vaccines) and methods of inducing an immune response in a subject in need thereof are provided.
Absstract of: US20260015620A1
Methods for making synthetic gene clusters are described.
Absstract of: AU2024277588A1
Systems and methods for assessing risk for zoonotic disease, including salmonella, amongst an animal population at a production facility. A user can provide data in response to a plurality of data entry fields that can, at least partially, pertain to a procedure, operation, and/or equipment at the production facility. For each data entry field, the data provided by the user can be assigned a value. The value can correspond to predetermined value of a predetermined response that is identified as corresponding to the user inputted data. The assigned value can be adjusted by a weighted factor, which may correspond to a predicted impact the actions or information reflected by the user inputted data may have on the prevention of zoonotic disease. The assigned and/or adjusted values can be compiled to generate a risk assessment score, which can be used to determine a food safety index score and/or food safety plan.
Absstract of: US20260007731A1
The present invention relates to intranasal bacterial polysaccharide conjugate nanoemulsion vaccines and methods of using the same for inducing an immune response to a bacterial polysaccharide.
Absstract of: KR20260003546A
본 발명은 돼지 살모넬라성 장염 유발 병원균을 검출할 수 있는 프라이머 세트에 관한 것으로, 본 발명에 따른 프라이머 세트를 이용하여 중합효소 연쇄반응을 통해 돼지 살모넬라성 장염 유발 병원균을 신속, 정확하게 검출할 수 있고, 검출한계가 낮아 소량의 돼지 가검물 시료로부터 병원균을 검출하여 감염병을 조기에 진단할 수 있다.
Absstract of: CN120677168A
The present invention relates to a non-viable bacterial cell in which an immunogenic polypeptide fused to an autotransporter comprising a transmembrane linker and a transporter domain is displayed on the surface of the cell, as well as to formulations comprising such non-viable cells. The formulations are useful as oral vaccines.
Absstract of: MX2025014302A
The invention relates to direct-fed microbials for use in <i>E. coli, Salmonella, </i>and/or <i>Clostridium</i> inhibition in animals. More particularly, the invention relates to isolated <i>Bacillus</i> strains CM256 (NRRL No. B-67706), CM857 (NRRL No. B-67705), CM978 (NRRL No. B-67703), CM1004 (NRRL No. B-67708), and MDG1607 (NRRL No. B-67666), and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use. The invention also relates to the use of isolated <i>Bacillus</i> strains CM256 (NRRL No. B-67706), CM857 (NRRL No. B-67705), CM978 (NRRL No. B-67703), and CM1004 (NRRL No. B-67708), and strains having all of the identifying characteristics of these strains, to treat plants having diseases caused by <i>E. coli, Salmonella, </i>and/or <i>Clostridium</i>.<u> </u>
Absstract of: CN121248735A
本发明属于生物技术领域，具体涉及一种具有增强TLR5配体活性的鞭毛蛋白突变体及其应用。选择鼠伤寒沙门氏菌鞭毛蛋白一个氨基酸突变位点，通过定点突变技术，利用大肠杆菌系统表达重组蛋白，经体外实验验证显示出良好的生物学活性，与野生型鞭毛蛋白突变体相比，能够更好的激活TLR5配体活性，为增强鞭毛蛋白佐剂和疫苗活性提供了良好的基础。
Absstract of: WO2026006835A1
Disclosed are engineered outer membrane proteins (OMPs) that comprise one or more extracellular loops from the Salmonella enterica serovar Typhimurium protein PagC or a functional portion thereof. Methods of expressing the engineered outer membrane proteins in a cell, such as a Gram-negative bacteria, to increase the production of outer membrane vesicles are also provided.
Absstract of: CN121248736A
本发明属于生物技术领域，具体涉及一种能够增强人源TLR5结合亲和力的鼠伤寒沙门菌鞭毛蛋白及其应用。本发明通过筛选并确定鞭毛蛋白的关键氨基酸突变位点，采用定点突变技术在大肠杆菌系统中实现重组表达。经体外实验验证，该衍生物能够显著激活TLR5配体功能。本发明解决了现有鞭毛蛋白在激活人源TLR5活性方面效果有限的问题，为鞭毛蛋白在疫苗、免疫治疗剂以及放射防护剂领域的应用提供了新的技术方案和理论基础。
Absstract of: CN121227763A
一种将猪霍乱沙门氏菌进行低内毒化改造的方法及其应用，它涉及疫苗领域，本发明通过基因工程技术对猪霍乱沙门氏菌弱毒株SC014的lipid A修饰，对猪霍乱沙门氏菌进行低内毒素化改造，成功构建了低内毒素的猪霍乱沙门氏菌突变体。改造后的猪霍乱沙门氏菌及其外膜囊泡在显著降低内毒素活性的同时，仍能有效激活免疫反应，实现了安全性与有效性的兼顾，为开发新型疫苗提供了新的思路和方法。
Absstract of: US2025387373A1
In one aspect, the disclosure relates to compositions and methods for dispersing exiting Salmonella biofilms and inhibiting formation of Salmonella biofilms. In various aspects, the disclosed compositions can be used in methods of treating a persistent Salmonella infection, including an asymptomatic infection. Such infections can colonize a variety of tissues, including the gall-bladder. Also disclosed are methods of treating typhoid fever. Also disclosed are methods for mitigating or preventing secondary outbreaks of typhoid fever by treating asymptomatic subjects who had been symptomatic for typhoid fever at a previous time. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Absstract of: CN120712079A
The present invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition comprising killed intact bacteria intended for use in mammals and birds, said bacteria being wrapped with a cationic agent, in particular cationic nanoparticles.
Absstract of: WO2025255902A1
A primer and probe for detecting Salmonella pullorum, and a kit. The primer comprises SP-F and SP-R for detecting the target sequence of the Salmonella pullorum (SP) citE2 gene, and the probe is modified with a fluorescent reporter group and a fluorescent quenching group. By means of providing the primer pair of SP-F and SP-R, which pair specifically binds to the target sequence of the citE2 gene, and combining the primer pair with the probe, whic is used for specific recognition, the accurate and sensitive detection of Salmonella pullorum can be realized.
Absstract of: MX2025009214A
The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.
Absstract of: KR20250175381A
본 발명은 항암 물질인 아르기닌 디이미나아제 (arginine deiminase; ADI)를 발현하는 항종양 박테리아 균주 및 이의 용도에 관한 것으로, 본 발명에 따른 항암 물질 생산 시스템이 도입된 면역 활성능이 있는 살모넬라 균주는 우수한 면역 항암 효능을 나타내어, 기존 항암제와 함께 또는 독립적으로 암의 치료제로 사용될 수 있다.
Absstract of: CN121142039A
本发明公开了一种CeO2‑Au复合材料结合TDN‑MultiApt形成的MNP‑DNA‑Apt复合体及制备方法与应用，所述的复合体是通过下述方法制备得到的：先构建立方体c‑CeO2‑Au纳米颗粒，再构建DNA‑CeO2‑Au探针（DA探针），然后利用四个单链DNA样品构建TDN结构，并通过碱基互补配对与适配体Apt链接，形成TDN‑MultiApt；TDN‑MultiApt通过抗原‑抗体反应和碱基互补配对分别与链霉亲和素修饰的磁珠MNP和DA探针结合形成MNP‑DNA‑Apt复合体，即形成MDA探针。本发明中的立方体CeO2‑Au结合TDN‑MultiApt比色传感系统突破了传统的基于培养和其他分子诊断技术的局限性，该系统通过比色模式进行检测，适用于现场快速检测，突出了其作为现场检测解决方案的潜力。
Absstract of: WO2024197078A2
Provided herein are compositions and methods for treating benign nervous system tumors, including schwannomas, using attenuated mutants of Salmonella typhimurium comprising a spiC deletion, and, optionally, one or more checkpoint inhibitors.
Absstract of: US2025375435A1
Disclosed herein are compositions and methods for treating a Salmonella infection. Disclosed herein are compositions and methods for inhibiting FraB in Salmonella. Disclosed herein are methods of increasing 6-phospho-fructose-aspartate within Salmonella bacteria.
Absstract of: US2025377362A1
The invention provides analytical methods for identifying and quantifying complex glycoconjugate compositions, in particular for the analysis of a glycoconjugate in a sample comprising at least 4 glycoconjugates.
Absstract of: US20260048111A1
The present disclosure relates to the technical field of medicine, and in particular to a pharmaceutical composition, preparation method and use thereof. The pharmaceutical composition includes a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient. The first active ingredient is a microbial agent, including one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi. The second active ingredient includes polyinosinic acid, polycytidylic acid, and vitamin. The pharmaceutical composition of the present disclosure pertains to an artificial active immunotherapy for tumors. It can “stimulate” the entire immune system, making the therapy of using bacteria to activate the human immune system to kill cancer cells highly stable and reliable. This composition can significantly save and prolong the lives of cancer patients while exhibiting extremely high safety, minimal toxic side effects, and low production costs.
Absstract of: WO2025246011A1
Provided are a method for enhancing the immunogenicity of a recombinant protein antigen and use thereof. The method comprises conjugating a polysaccharide with a recombinant protein antigen to form a nano-scale protein antigen. The polysaccharide is selected from sodium hyaluronate, chitosan, glucan, fucoidan, and sodium alginate. The recombinant protein antigen is a protein antigen derived from a bacterium. The bacterium belongs to the genus of Staphylococcus, Neisseria, Klebsiella, Escherichia, Clostridium, Salmonella, Shigella, Pseudomonas, Acinetobacter, Bordetella, Enterococcus, Haemophilus, Mycobacterium, or Streptococcus. The method not only improves the immunogenicity of the recombinant protein antigen, but also overcomes the defects of competitive immunoregulation and poor immune enhancement effects caused by bacterial capsular polysaccharide modification. The method also has the advantages of high clinical application value, simple starting material acquisition, low cost, good process stability, ease in scale expansion, high safety, and the like.
Absstract of: WO2024156739A1
The invention relates to a method for identifying a multi-parameter phenotype of microbiota. The method comprises (i) providing a sample comprising microbiota, (ii) labeling said microbiota with multiple labels, each of which binds a phenotypic parameter of said microbiota, (iii) detecting an intensity of the labelled phenotypic parameters of single cells of the microbiota by flow cytometry, and (iv) segmenting the single cells into bins based on the intensities of detected phenotypic parameters, wherein the distribution of single cells in bins represents a multi-parameter phenotype of said microbiota. The invention further relates to a system for identifying a multi-parameter phenotype of intestinal microbiota, a kit for identifying a multi-parameter phenotype of intestinal microbiota and methods for diagnosing a medical condition associated with microbiota, for example an inflammatory condition, such as an inflammatory bowel disease, in a subject.
Nº publicación: CN121049237A 02/12/2025
Applicant:
山东省血液中心
Absstract of: CN121049237A
本发明公开一种冰箱沉降菌检测方法及检测装置，涉及检测技术领域，技术方案为，先采用Aptamer和Toehold switch策略构建检测载体作为检测介质；再将其置于待检测空间，形成固定形状和面积的检测区域并与空气接触；接着对检测区域进行图像采集，识别颜色变化区域；最后分析图像获取沉降菌检测结果。此方法无需复杂培养分离，简化流程、缩短检测时间；通过图像采集与颜色分析直观快速出结果，操作便捷。相比传统方法，它克服了费时费力、需多法结合的弊端，能快速准确检测医用冰箱沉降菌，预防交叉感染，保障药品、血液安全，具有高特异性、灵敏度，应用潜力大。
BOPI
Electronic site
